These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37164738)

  • 1. A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab.
    Fukura S; Takei M; Takeuchi S; Tayama T; Ono A; Ichihara Y; Shichijo K; Suzuki Y; Mori K; Kondo S
    J Med Invest; 2023; 70(1.2):294-297. PubMed ID: 37164738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan.
    Ikeuchi A; Kakiuchi T; Ibi A; Matsuo M
    Clin J Gastroenterol; 2021 Feb; 14(1):146-151. PubMed ID: 33040281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
    Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
    Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.
    Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A
    Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy.
    Ishihara H; Watanabe T; Kumei S; Kume K; Yoshikawa I; Harada M
    Clin J Gastroenterol; 2024 Feb; 17(1):46-51. PubMed ID: 38041760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special considerations for biologic medications in pediatric ulcerative colitis.
    Jerger L; Hyams JS
    Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report.
    Oki Y; Nagano S; Ishikawa Y; Yamada T; Ichimori T; Uchida K
    J Med Case Rep; 2023 May; 17(1):227. PubMed ID: 37254193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Feb; 101(7):e28873. PubMed ID: 35363198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
    Narula N; Wong ECL; Marshall JK; Colombel JF; Dulai PS; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1588-1597.e3. PubMed ID: 34329776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
    Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.